Efficacy and safety of burosumab compared with conventional therapy in patients with X-linked hypophosphatemia: A systematic review
Manjunath Havalappa Dodamani, Samantha Cheryl Kumar, Samiksha Bhattacharjee, Rohit Barnabas, Sandeep Kumar, Anurag Ranjan Lila, Saba Samad Memon, Manjiri Karlekar, Virendra C. Patil, Tushar Bandgar
Abstract
< 0.001) with resultant clinical improvement. Burosumab treatment was well tolerated, with only mild treatment-related adverse effects. The present review indicates a potential role for burosumab in improving rickets, deformities, and growth in children with XLH. Given its superior efficacy and safety profile, burosumab could be an effective therapeutic option in children. We suggest further studies comparing burosumab versus conventional therapy in children and adults with XLH.
Topics & Concepts
MedicineHypophosphatemiaInternal medicineFibroblast growth factor 23Meta-analysisConfidence intervalCalcitriolMEDLINEGastroenterologyVitamin D and neurologyParathyroid hormoneCalciumLawPolitical scienceParathyroid Disorders and TreatmentsHeterotopic Ossification and Related ConditionsBone health and treatments